Tanepon Clinical Review Evidence-based insight on pain therapeutics and trials

Tanepon Clinical Review

Evidence-based insight on pain therapeutics and trials

Latest Articles

The Statistic That Was Signed Years Before You Enrolled: How Endpoint Negotiation Shapes a Pain Drug's Fate
Regulatory Analysis

The Statistic That Was Signed Years Before You Enrolled: How Endpoint Negotiation Shapes a Pain Drug's Fate

A pain drug can ease symptoms in real patients and still fail its pivotal trial — because the yardstick it must clear was fixed during closed-door negotiations with regulators long before the first volunteer enrolled. This analysis explains how primary endpoints and responder definitions are set, and why identical molecules can produce opposite verdicts in different programs.
Prior Authorization for a Drug With No Indication: How US Insurers Handle the Financial Limbo of Unproven Pain Therapies
Regulatory Analysis

Prior Authorization for a Drug With No Indication: How US Insurers Handle the Financial Limbo of Unproven Pain Therapies

When a pain therapy exists only in trials or regulatory limbo, insurers face a coverage question with no clean answer. This report examines how payers, reimbursement specialists, and patient advocates navigate the gray zone between experimental and approved.
Before the First Human Dose: What Canine Osteoarthritis Studies Revealed About NGF Inhibitors — and Why the Signal Took Years to Land
Drug Pipeline

Before the First Human Dose: What Canine Osteoarthritis Studies Revealed About NGF Inhibitors — and Why the Signal Took Years to Land

Long before Phase III imaging sub-studies confirmed accelerated joint destruction in humans, veterinary researchers had documented rapid cartilage breakdown in dogs treated with nerve growth factor inhibitors. This review examines the companion-animal evidence, what it predicted accurately, and why its implications were slow to shape human trial design.
When the Real Drug Is Gone, the Copycats Arrive: Inside the Compounding Gray Market for Unavailable Pain Therapies
Regulatory Analysis

When the Real Drug Is Gone, the Copycats Arrive: Inside the Compounding Gray Market for Unavailable Pain Therapies

When a promising pain therapy never reaches the pharmacy shelf, some patients and clinicians turn to compounded analogs or overseas suppliers. We examine what federal and state rules actually permit, where the safety record thins out, and how patients can protect themselves before accepting a 'copy' of a drug that was never approved.
The Referral File Nobody Reads: Rebuilding Your Pain Records So a Specialist Actually Sees You
Drug Pipeline

The Referral File Nobody Reads: Rebuilding Your Pain Records So a Specialist Actually Sees You

Chronic pain referrals in the US health system often stall not because treatment options are missing, but because the patient's history arrives fragmented. We spoke with pain specialists about what a usable referral file looks like — and how disciplined self-documentation can change the trajectory of a specialist evaluation.
Lessons Written in Adjudication: How a Troubled Pain Program Rewired Modern Trial Design
Drug Pipeline

Lessons Written in Adjudication: How a Troubled Pain Program Rewired Modern Trial Design

The NGF inhibitor programs of the 2010s stumbled, but their methodological fingerprints are everywhere in today's pain research. From independent joint-adjudication panels to mandatory imaging sub-studies, the hard lessons of tanezumab became the playbook for safer, smarter trials.
Regulatory Analysis

The Price Tag of a Drug That Never Shipped: What Tanezumab's Ghost Tells Us About Pain-Therapy Economics

Tanezumab never reached a pharmacy shelf, yet its projected cost structure continues to shape how payers, regulators, and manufacturers think about non-opioid pain therapy. This analysis asks whether insurance coverage has become a silent variable in the approval calculus for chronic pain drugs.
Daily Check-Ins, Delayed Signals: What Smartphone Pain Diaries Actually Deliver to Regulators
Drug Pipeline

Daily Check-Ins, Delayed Signals: What Smartphone Pain Diaries Actually Deliver to Regulators

Electronic diaries and wearable sensors have quietly replaced the clipboard in modern analgesic trials, streaming thousands of data points per participant to sponsors and regulators. The question is whether this flood of patient-generated evidence clarifies a drug's risk-benefit profile or buries rare safety signals under everyday noise.
The Public Database Most Patients Skip: Learning to Read FAERS Before the Headlines Do
Regulatory Analysis

The Public Database Most Patients Skip: Learning to Read FAERS Before the Headlines Do

The FDA Adverse Event Reporting System holds millions of raw, unfiltered accounts of drug side effects — including signals from pain therapeutics that never made the evening news. This guide explains how to search it, what its numbers can and cannot tell you, and why a single report is a question rather than an answer.
One Dose, Many Bodies: How Age, Weight, and Kidney Function Rewrite the Risk Math in Pain Trials
Drug Pipeline

One Dose, Many Bodies: How Age, Weight, and Kidney Function Rewrite the Risk Math in Pain Trials

Clinical trials often report a single 'safe dose,' but that number hides enormous variation in how individual bodies handle a drug. We explain pharmacokinetics in plain language, why subpopulation analyses matter to regulators, and what older adults should ask before enrolling in a pain study.
Under Treatment by Design: What Control-Group Volunteers in Pain Trials Actually Sign Up For
Regulatory Analysis

Under Treatment by Design: What Control-Group Volunteers in Pain Trials Actually Sign Up For

Control-arm participants in experimental pain drug trials are often described as receiving 'standard care' — but the reality is more complicated. This review examines rescue medication protocols, escalation rules, and whether consent forms adequately prepare volunteers for prolonged, deliberately unrelieved pain.
Counting the Cost of a Molecule That Never Went on Sale
Regulatory Analysis

Counting the Cost of a Molecule That Never Went on Sale

Tanezumab never reached a pharmacy shelf, yet the economics behind it were fully formed years before regulators said no. We examine how developers price pain therapies that may never be approved, and what a rejected drug's paper value reveals about the U.S. market.
After the Verdict: How a Handful of U.S. Patients Can Still Legally Receive a Rejected Pain Drug
Regulatory Analysis

After the Verdict: How a Handful of U.S. Patients Can Still Legally Receive a Rejected Pain Drug

An FDA rejection does not always mean the last dose has been given. Expanded access programs, investigator-initiated studies, and compassionate use protocols form a quiet back channel through which investigational drugs can keep reaching patients — if they know the doors exist.
Reading the Films Before the Headlines: How Imaging Sub-Studies Reshaped the NGF Inhibitor Story
Regulatory Analysis

Reading the Films Before the Headlines: How Imaging Sub-Studies Reshaped the NGF Inhibitor Story

Radiographic sub-studies within the tanezumab program surfaced a finding that no patient-reported pain scale could capture: rapidly progressive osteoarthritis visible on X-ray and MRI. This article explains how imaging endpoints became the decisive evidence in the regulatory review of NGF inhibitors, and why future analgesic trials will be judged as much by their films as by their questionnaires.
New Hands, Old Molecule: Following a Rejected Pain Drug Through Its Corporate Afterlife
Regulatory Analysis

New Hands, Old Molecule: Following a Rejected Pain Drug Through Its Corporate Afterlife

When a pain medication fails at the FDA, the molecule rarely dies — it changes hands. We trace how licensing deals, acquisitions, and quiet repositioning efforts give rejected compounds a second act, and how patients can track the paper trail before a relaunch arrives under a new name.
The Counter Conversation: What Community Pharmacists See Before the Rest of the Care Team Does
Regulatory Analysis

The Counter Conversation: What Community Pharmacists See Before the Rest of the Care Team Does

When a new non-opioid pain therapy finally clears its regulatory hurdles, it is the community pharmacist who fields the first real-world questions from patients. Their vantage point reveals practical truths about access, cost, and safety counseling that trial data alone cannot capture.
The Meeting Was Public. The Insight Wasn't: How to Mine an FDA Advisory Committee Transcript for a Drug's Real Risk Profile
Regulatory Analysis

The Meeting Was Public. The Insight Wasn't: How to Mine an FDA Advisory Committee Transcript for a Drug's Real Risk Profile

Press releases compress an eight-hour advisory committee meeting into a headline. The full transcript — free, public, and searchable — tells a far more textured story. This walkthrough shows patients and researchers how to read one like a clinician.
When the Trial Ends and the Drug Disappears: The Unanswered Questions of Pain-Trial Volunteers
Regulatory Analysis

When the Trial Ends and the Drug Disappears: The Unanswered Questions of Pain-Trial Volunteers

Thousands of Americans enroll each year in trials of experimental pain therapies, yet few consider what happens if the compound is never approved. This review examines post-trial obligations, safety follow-up, and the policy gaps that leave participants navigating the end of a study on their own.
Where Failed Drug Data Goes to Sleep — and How Researchers Wake It Up
Regulatory Analysis

Where Failed Drug Data Goes to Sleep — and How Researchers Wake It Up

When a pharmaceutical program is shelved, the clinical trial data behind it doesn't simply vanish — but it doesn't always surface either. This examination traces the regulatory pathways, disclosure obligations, and advocacy efforts that determine whether abandoned pain-drug datasets see daylight.
One Protein, Two Decades, and a Cautionary Tale: The Biology Behind NGF-Targeting Pain Drugs
Drug Pipeline

One Protein, Two Decades, and a Cautionary Tale: The Biology Behind NGF-Targeting Pain Drugs

Nerve growth factor went from Nobel Prize-winning discovery to the center of pain research's costliest setback. This explainer traces the biology — why blocking NGF relieves pain so effectively, and why the same mechanism can accelerate joint collapse.